Ronny Martin
Overview
Explore the profile of Ronny Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elsaman H, Golubtsov E, Brazil S, Ng N, Klugherz I, Martin R, et al.
Nat Commun
. 2024 Jul;
15(1):6312.
PMID: 39060235
Azole antifungals inhibit the sterol C14-demethylase (CYP51/Erg11) of the ergosterol biosynthesis pathway. Here we show that the azole-induced synthesis of fungicidal cell wall carbohydrate patches in the pathogenic mold Aspergillus...
2.
Stieber H, Junghanns L, Wilhelm H, Batliner M, Aldejohann A, Kurzai O, et al.
Mycoses
. 2024 Mar;
67(4):e13723.
PMID: 38551121
Background: The emergence of the pathogenic yeast Candida auris is of global concern due to its ability to cause hospital outbreaks and develop resistance against all antifungal drug classes. Based...
3.
Schrenker B, Zimmermann A, Koch T, Walther G, Martin R, Kampik D, et al.
Int J Med Microbiol
. 2024 Jan;
314:151602.
PMID: 38280372
Purpose: Fusarium keratitis is a severe infection of the anterior eye, frequently leading to keratoplasty or surgical removal of the affected eye. A major risk factor for infection is the...
4.
Aldejohann A, Menner C, Thielemann N, Martin R, Walther G, Kurzai O
Antimicrob Agents Chemother
. 2024 Jan;
68(2):e0132423.
PMID: 38206004
Invasive candidiasis is a major hospital-acquired infection. Usually, echinocandins are considered first-line treatment. However, resistant phenotypes have emerged. Ibrexafungerp (IBX) is a new antifungal substance with potent anti- activity. We...
5.
Aldejohann A, Martin R, Hecht J, Haller S, Rickerts V, Walther G, et al.
Dtsch Arztebl Int
. 2023 Sep;
120(27-28):447-478.
PMID: 37661316
No abstract available.
6.
Garbe E, Thielemann N, Hohner S, Kumar A, Vylkova S, Kurzai O, et al.
Microbiol Spectr
. 2023 Feb;
:e0025323.
PMID: 36786567
The formation of hyphae is a key virulence attribute of Candida albicans as they are required for adhesion to and invasion of host cells, and ultimately deep-tissue dissemination. Hyphae also...
7.
Thielemann N, Herz M, Kurzai O, Martin R
Comput Struct Biotechnol J
. 2022 Feb;
20:608-614.
PMID: 35116136
The human body is a dynamic ecosystem consisting of millions of microbes which are often comprised under the term microbiome. Compared to bacteria, which count for the overwhelming majority of...
8.
Aldejohann A, Herz M, Martin R, Walther G, Kurzai O
JAC Antimicrob Resist
. 2021 Aug;
3(3):dlab122.
PMID: 34377983
Background: is the second leading fungal pathogen causing candidaemia and invasive candidiasis in Europe. This yeast is recognized for its rapid ability to acquire antifungal drug resistance. Objectives: We systematically...
9.
Dunker C, Polke M, Schulze-Richter B, Schubert K, Rudolphi S, Gressler A, et al.
Nat Commun
. 2021 Jun;
12(1):3899.
PMID: 34162849
The ability of the fungal pathogen Candida albicans to undergo a yeast-to-hypha transition is believed to be a key virulence factor, as filaments mediate tissue damage. Here, we show that...
10.
Sturm L, Geissel B, Martin R, Wagener J
Front Microbiol
. 2020 Jun;
11:1017.
PMID: 32528443
Azole resistance of the fungal pathogen is an emerging problem. To identify novel mechanisms that could mediate azole resistance in , we analyzed the transcriptome of a mitochondrial fission/fusion mutant...